This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/kegg-drug/
n14http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB03516/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03516
rdf:type
n3:Drug
n3:description
Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and basal cell cancer of the skin. Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU).
n3:generalReferences
# Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI: A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. Cancer Invest. 2006 Feb;24(1):9-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16466986 # Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI: A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):779-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14967434 # Yip D, Karapetis C, Strickland AH, Steer C, Holford C, Knight S, Harper P: A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Ann Oncol. 2003 Jun;14(6):864-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12796023
n3:group
investigational
n3:indication
For the treatment of cancer in combination with 5-fluorouracil.
owl:sameAs
n14:DB03516
dcterms:title
Eniluracil
adms:identifier
n7:39327 n8:DB03516 n9:50124202 n10:12014705 n11:D03998 n12:43157
n3:mechanismOfAction
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
n3:synonym
Compound 776C 5-Ethynyluracil 5-ethynyl-2,4(1H,3H)-Pyrimidinedione
n3:IUPAC-Name
n4:271B4FCB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4FD1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4FD0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4FCD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4FCE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4FCF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4FC9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4FCA-363D-11E5-9242-09173F13E4C5 n4:271B4FC7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4FC8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4FD7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4FD8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4FD2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4FD3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4FD5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4FD4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4FD6-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59989-18-3
n3:category
n3:Bioavailability
n4:271B4FDD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4FDF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4FE0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4FDC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4FDB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4FDE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4FCC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4FD9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4FDA-363D-11E5-9242-09173F13E4C5